Cell Signaling and Signal Transduction Inhibitors
Get access to all handy features included in the IVIS website
- Get unlimited access to books, proceedings and journals.
- Get access to a global catalogue of meetings, on-site and online courses, webinars and educational videos.
- Bookmark your favorite articles in My Library for future reading.
- Save future meetings and courses in My Calendar and My e-Learning.
- Ask authors questions and read what others have to say.
Key information
The objective of this module is to provide an overview of signal transduction in both normal and neoplastic cells, how dysregulated signaling contributes to tumor growth and methods used to target aberrant signaling in cancer cells. This module covers the following subjects:
- Normal signal transduction and cellular homeostasis
- Major signal transduction pathways in cells (PI3 kinase, MAP Kinase, etc.)
- Causes of dysregulated signaling in cancer cells (e.g., mutations, etc.)
- Role of dysregulated signaling in supporting cancer cell growth/survival
- Methods and mechanisms to aberrant signal transduction in cancer (e.g., small molecular inhibitors)
- Resistance to small molecule inhibitors
- Application of small molecule inhibitors to veterinary cancers
Presenter - Cheryl London, DVM, PhD, DACVIM (Oncology)
- Anne Engen and Dusty Professor of Comparative Oncology, Cummings School of Veterinary Medicine and School of Medicine and School of Medicine at Tufts University
- Associated Faculty Professor, Ohio State University College of Veterinary Medicine
The ACVIM has developed nine (9) Science of Veterinary Oncology (SOVO) online courses that are currently available and complimentary for ACVIM members with five (5) more in development and coming soon. These modules offer foundational building blocks of core knowledge areas pertaining to veterinary oncology and were developed based on the Job Task Analysis review performed in 2016. All modules are led by industry experts and each module is RACE-approved.
All Sessions:
- Cancer Bioenergetics - Douglass H. Thamm, VMD, DACVIM (Oncology)
- Cancer Stem Cells - Professor David Argyle, PhD and Lisa Pang, PhD
- Cell Signaling and Signal Transduction Inhibitors - Cheryl London, DVM, PhD, DACVIM (Oncology)
- Discovery and Evaluation of Anticancer Drugs - David Lowery, PhD
- Epigenetics of Cancer - Jeffrey Bryan, DVM, MS, Phd, DACVIM (Oncology)
- Genomic Instability - Kelly R. Hume, DVM, DACVIM (Oncology)
- Invasion and Metastasis - Robert B. Rebhun, DVM, PhD, DACVIM (Oncology)
- Pharmacology of Cancer Drugs and Resistance - Luke Wittenburg, DVM, PhD, DACVCP
- Tumor Microenvironment - Jamie Modiano, VMD, PhD